The change in many chemical companies’ product portfolio away from commodities to customer-specific specialties is one of the current challenges facing the process industry.
The change in many chemical companies’ product portfolio away from commodities to customer-specific specialties is one of the current challenges facing the process industry.
The change in many chemical companies’ product portfolio away from commodities to customer-specific specialties is one of the current challenges facing the process industry.
The change in many chemical companies’ product portfolio away from commodities to customer-specific specialties is one of the current challenges facing the process industry.
The change in many chemical companies’ product portfolio away from commodities to customer-specific specialties is one of the current challenges facing the process industry.
Iris.ai was founded at Singularity University at NASA Ames Research Park in 2015. Challenged to come up with an idea that would positively impact the lives of 1 billion people, the team was formed and problem areas were explored.
In 2019, the pharmaceutical industry invested $182 billion in drug development, but only 48 drugs were approved for use.
The fate of the agrochemical innovation, development, product launch and production are strongly linked to the parallel development of the fine chemicals and custom manufacturing industry.
The change in many chemical companies’ product portfolio away from commodities to customer-specific specialties is one of the current challenges facing the process industry.
New therapies to address unmet and emerging medical needs are being discovered at an explosive rate, building on rapid advances in molecular biology and genetics.
As customers engage in more multi-channel interactions, having a deep understanding of these journeys is an essential component for the customer service function, and for ensuring excellence in the overall customer experience.
Rentschler Biopharma SE, headquartered in Laupheim, Germany, is a leading, family-owned, full-service biopharma CDMO. Owing to agile decision making and efficient processes, Rentschler Biopharma is the preferred outsourcing partner for bioprocess development, cGMP manufacturing, as well as elaboration of product approval strategies for over 150 clients worldwide.
